

MGI and Bio-Medical Science to deliver cutting-edge sequencing platforms to South Korea

14 September 2023 | News

To facilitate more widespread adoption of genomics, multi-omics, metagenomics and related business locally in South Korea



MGI, a China-based company, has announced the signing of a Memorandum of Understanding (MoU) with Korean firm Bio-Medical Science Co. (BMS) to expand genomics solutions in South Korea by leveraging MGI's cutting-edge technology.

The MoU is expected to reach collaborations in localising MGI's manufacturing capability in selected genetic sequencers and reagents in South Korea via BMS, which will provide the market with state-of-the-art products that have been adapted to local needs, thereby helping advance genomic research and clinical diagnostics.

BMS and MGI will work to reach collaborations relating to the licensing, supply, manufacturing and distribution of selected genetic sequencers and reagents in South Korea. Leveraging BMS' strong local network for sales and distribution and MGI's innovative technology, South Korea is set to further tap into the potential of larger scale genomics, clinical studies and even microbiome.

The relationship between MGI and BMS can be traced back to 2019, when BMS became the first company in Asia Pacific to join MGI's Global Sequencer User Programme (SUP) to promote the development of genetic technologies and applications through customised products and services. Earlier this year, the two companies also partnered to establish a joint Customer Experience Center (CEC) in South Korea, aiming to provide local customers with first-hand access to MGI's newer technologies and products.